SG11201811595SA - Liponucleotide-based therapy for ards - Google Patents

Liponucleotide-based therapy for ards

Info

Publication number
SG11201811595SA
SG11201811595SA SG11201811595SA SG11201811595SA SG11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA
Authority
SG
Singapore
Prior art keywords
international
cdp
rule
ards
pct
Prior art date
Application number
SG11201811595SA
Inventor
Ian Davis
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of SG11201811595SA publication Critical patent/SG11201811595SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 HOE 3E1 0 0111101111110111101010 111111111011011# Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/005527 Al 04 January 2018 (04.01.2018) WIP0 I PCT (51) International Patent Classification: A61K 31/513 (2006.01) A61K 31/70 (21) International Application Number: (22) International Filing Date: 27 June 2017 (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/355,096 27 June 2016 (27.06.2016) (71) Applicant: OHIO STATE INNOVATION DATION [US/US]; 1524 North High Street, OH 43201 (US). (72) Inventor: DAVIS, Ian, Christopher; 5608 ye, Hilliard, OH 43026 (US). (74) Agent: GILES, P. Brian Giles; Thomas 3200 Windy Hill Road, Suite 1600E, Atlanta, PCT/US2017/039545 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (27.06.2017) (84) Designated States (unless otherwise indicated, for every English kind of regional protection available): ARIPO (BW, GH, English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, FOUN- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Columbus, KM, ML, MR, NE, SN, TD, TG). Hardwell Dri- Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Horstemeyer LLP, — as to the applicant's entitlement to claim the priority of the GA 30339 earlier application (Rule 4.17(iii)) — of inventorship (Rule 4.17(iv)) for every Published: AG, AL, AM, — with international search report (Art. 21(3)) BR, BW, BY, BZ, DJ, DK, DM, DO, GM, GT, HN, (US). = (81) Designated States (unless otherwise indicated, = kind of national protection available): AE, _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, CA, CH, CL, CN, CO, CR, CU, CZ, DE, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, (54) Title: LIPONUCLEOTIDE-BASED THERAPY FOR ARDS - ... .. - .. ... I I , . . • I 1 I = 2 = = = — E` ) = c . ci = 8 = 1 = _ = 0 = 12_ 0_ 0 1-1 IN 0 N kl) kl) 0 0 -.... 00 C (57) : Compositions and method are \" tains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP- ,., ethanolamine, and CDP-diacylglycerol (CDP-DAG) 2 MOCK 2 6 MOCK 6 FIGURE 1 therefore disclosed for treating ARDS. In particular, disclosed a composition that con- in a pharmaceutically acceptable carrier for use in treating ARDS.
SG11201811595SA 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards SG11201811595SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662355096P 2016-06-27 2016-06-27
PCT/US2017/039545 WO2018005527A1 (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Publications (1)

Publication Number Publication Date
SG11201811595SA true SG11201811595SA (en) 2019-01-30

Family

ID=60786443

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811595SA SG11201811595SA (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Country Status (9)

Country Link
US (2) US10874684B2 (en)
EP (2) EP3474853A4 (en)
JP (1) JP2019518798A (en)
KR (1) KR20190022682A (en)
CN (1) CN109475554A (en)
AU (1) AU2017289278A1 (en)
CA (1) CA3029005A1 (en)
SG (1) SG11201811595SA (en)
WO (1) WO2018005527A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475554A (en) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 ARDS treatment based on Liponucleotide
WO2019005898A1 (en) * 2017-06-27 2019-01-03 Ohio State Innovation Foundation Liponucleotide-based therapy for copd
EP4125857A4 (en) * 2020-03-31 2024-04-17 Diffusion Pharmaceuticals Llc The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
EP4142709A4 (en) * 2020-05-01 2024-05-22 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
WO2023173043A1 (en) * 2022-03-11 2023-09-14 Arizona Board Of Regents On Behalf Of Arizona State University Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection
WO2023177995A2 (en) * 2022-03-18 2023-09-21 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
WO1989003837A1 (en) * 1987-10-28 1989-05-05 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
MX9700109A (en) * 1994-07-01 1997-04-30 Pro Neuron Inc Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis.
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
EP2301550A1 (en) * 2001-07-13 2011-03-30 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
DK1453844T3 (en) * 2001-11-21 2014-02-10 Univ Aarhus APPLICATION OF GLYCOSIDES OF MONO- AND DIACYLGYLCEROL AS ANTI-INFLAMMATORY AGENTS
AU2006251569B2 (en) * 2005-05-23 2012-06-21 Massachusetts Institute Of Technology Compostions containing pufa and/or uridine and methods of use thereof
CN101495490B (en) * 2005-05-23 2018-05-08 麻省理工学院 Composition and its application method containing polyunsaturated fatty acid and/or uridine
CN109475554A (en) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 ARDS treatment based on Liponucleotide
EP3645010A4 (en) * 2017-06-27 2021-03-24 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma
WO2019005898A1 (en) * 2017-06-27 2019-01-03 Ohio State Innovation Foundation Liponucleotide-based therapy for copd

Also Published As

Publication number Publication date
EP3474853A1 (en) 2019-05-01
EP4292651A2 (en) 2023-12-20
WO2018005527A1 (en) 2018-01-04
US20190134074A1 (en) 2019-05-09
KR20190022682A (en) 2019-03-06
JP2019518798A (en) 2019-07-04
AU2017289278A1 (en) 2019-01-17
US10874684B2 (en) 2020-12-29
EP4292651A3 (en) 2024-03-13
CA3029005A1 (en) 2018-01-04
EP3474853A4 (en) 2020-02-19
US20210069225A1 (en) 2021-03-11
CN109475554A (en) 2019-03-15

Similar Documents

Publication Publication Date Title
SG11201811595SA (en) Liponucleotide-based therapy for ards
SG11201909949XA (en) Targeted immunotolerance
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807187XA (en) Binding members to pd-l1
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201903155XA (en) Pharmaceutical compounds
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations